Halo Pharma's transition to a standalone CDMO allows a concentrated focus on drug product services, enhancing technical ...
PharmTech is rebranding to strengthen its commitment to scientists, innovators, and executives in the pharmaceutical industry ...
Define Ventures’ new report provides a clear framework for how enterprise healthcare, particularly Big Pharma, is transitioning from AI exploration to execution. It focuses on core categories, ...
As pharmaceutical markets become more specialized and competitive, commercial and medical affairs teams must use technology and collaboration to make faster, better-informed decisions, Lance Hill, ...
Suzhou Zion Pharma Technology Co Ltd. has identified KRAS inhibitors, in particular GTPase KRAS G12D mutant and/or G13D mutant, reported to be useful for the treatment of cancer. Suzhou Zion Pharma ...
New global study of 250 pharma leaders shows rapid uptake of agentic AI; early adopters focus on market intelligence, patient support, compliance and data integration. As the industry seeks to grasp ...
Suzhou Zion Pharma Technology Co Ltd. has identified KRAS inhibitors, in particular GTPase KRAS G12D mutant and/or G13D mutant, reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results